Multiple myeloma (MM) is seldom curable and a majority of patients experience a relapse after initial responses. This has led to a particularly high demand for alternative treatments, such as those that target the CD38 surface antigen. MOR202 induces antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) mediated killing of multiple myeloma cells.
MOR202 is currently being tested in a phase 1/2a trial* in patients with relapsed/refractory myeloma. The study is evaluating the safety and preliminary efficacy of MOR202 as monotherapy and in combination with pomalidomide and lenalidomide plus dexamethasone.
First clinical data, which was presented at the ASCO 2015 meeting, showed that MOR202 was safe and tolerable. The antibody demonstrated best-in-class infusion tolerability with no infusion reactions in combination with dexamethasone when applied through a consistent 2-hour infusion. Additionally, MOR202 showed early signs of clinical activity with cases of long-lasting tumor control.
Preclinical data demonstrate the synergistic potential of MOR202 and established immunomodulatory agents (iMiDs) in relapsed/refractory multiple myeloma therapy. Either pomalidomide or lenalidomide enhanced the cytotoxic activity of MOR202 in vitro through multiple mechanisms, namely direct cytotoxicity, CD38 up-regulation and activation of effector cells. These findings support further investigation of MOR202 combination regimens in clinical trials.